Breaking News on Contract Research, Manufacturing & Clinical Trials

Headlines > Preclinical Research

Read more breaking news



Drugs moving into the clinic: 19

By Mike Nagle , 21-Jun-2007

The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.

Sponsor Name Indication Mechanism
Multiple Myeloma Research Consortium (MMRC) & Emory University Tipifarnib and Velcade (bortezomib) Oncology - relapsed or refractory multiple myeloma First-in-clinic farnesyl transferase inhibitor plus Ortho Biotech / Janssen Cilag's proteasome inhibitor
Novo Nordisk & Neose Technologies GlycoPEGylated Factor VIIa Cardiovascular - reduce bleeding in haemophilia Long-acting version of NovoSeven Coagulation Factor VIIa
StemCells Inc HuCNS-SC CNS - infantile and late infantile neuronal ceroid lipofuscinosis aka Batten disease purified human neural stem cells
CoMentis CTS-21166 CNS- Alzheimer's disease oral small molecule beta-secretase inhibitor
Intercell Vaccine formulated with IC31 Anti-infectives & vaccines - influenza Adjuvant designed to increase T-cell response and enable cross-strain protection
OSI Pharma- ceuticals OSI-906 Oncology - colorectal, prostate, non-small cell lung, breast and ovarian cancers Oral inhibitor of the insulin-like growth factor-1 receptor (IGF-1R)
Collegium Pharma- ceutical COL-003 Pain sustained release opioid formulation using oral delivery technology, DETERx, to act as an abuse deterrent
Altus Pharma- ceuticals ALTU-237 Hyperoxalurias and the possible prevention of recurrent kidney stones Orally-delivered crystalline formulation of an oxalate-degrading enzyme

Key Industry Events


Access all events listing

Our events, Shows & Conferences...